Patents by Inventor Michael Bröker

Michael Bröker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Structural phosphoprotein (pp28) of human cytomegalovirus (HCMV), the preparation and use thereof
    Patent number: 6733989
    Abstract: Structural phosphoprotein (pp28) of human cytomegalovirus (HCMV), the preparation and use thereof Expression of an SmaI fragment, which is about 1.0 kb in size, on the left-hand end of the HindIII R fragment makes it possible to synthesize, by genetic manipulation, a structural phosphoprotein of HCMV. This phosphoprotein, or immunogenic parts thereof, can be used as diagnostic aid or vaccine.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: May 11, 2004
    Assignee: Dade Behring Marburg GmbH
    Inventors: Michael Mach, Heidi Meyer, Michael Bröker, Leander Lauffer
  • Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins
    Patent number: 6300102
    Abstract: The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and the antibodies directed to the hybrid protein confer protection against an infection by Pseudomonas aeruginosa to laboratory animals or man.
    Type: Grant
    Filed: March 10, 1999
    Date of Patent: October 9, 2001
    Assignee: Chiron Behring GmbH & Co.
    Inventors: Bernhard Knapp, Klaus-Dieter Hungerer, Michael Bröker, Bernd-Ulrich von Specht, Horst Domdey
  • Process for the production of proteins
    Patent number: 6284520
    Abstract: The invention pertains to the field of recombinant DNA technology and concerns a method for the production of a protein heterologous to yeast in a homogenous form with the aid of Saccharomyces cerevisiae strain HT393 or a derivative thereof carrying a hybrid vector containing the genes for said protein.
    Type: Grant
    Filed: May 5, 1999
    Date of Patent: September 4, 2001
    Assignee: Novartis AG
    Inventors: Bernd Meyhack, Michael Bröker
  • Recombinant proteins with the immunoreactivity of hepatitis B virus e antigen (HBeAg), a process for the preparation thereof and the use thereof in immunoassays and vaccines
    Patent number: 6277631
    Abstract: Recombinant yeast expression vectors with the features indicated in the patent claims are described. These recombinant yeast expression vectors can be used for the preparation of HBeAg in yeast host organisms. Appropriate expression systems, transformed host organisms, diagnostic aids and medicinal agents are additionally described.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: August 21, 2001
    Assignee: Dade Behring Marburg GmbH
    Inventors: Michael Noah, Michael Bröker